πŸ‡ΊπŸ‡Έ FDA
Patent

US 8350079

Treprostinil formulation

granted A61PA61P11/00A61P11/06

Quick answer

US patent 8350079 (Treprostinil formulation) held by United Therapeutics Corporation expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Jan 08 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P11/00, A61P11/06, A61P13/12, A61P21/00